CXCL9 and neoplasm: Loss of IL-17 signaling also increased the expression of CXCR3, the cognate receptor for CXCL9/10/11 chemokines, likely reflecting an increased recruitment of CXCR3-expressing lymphocytes to the tumor (Fig. 3a).